A Randomized, Multicentric,Open label,Interventional study to evaluate the Efficacy and tolerability of two types of Amrutanjan Pain Balm for pain relief in patients with primary type of headache and body pain disorders.

Amrutanjan Health Care Limited0 个研究点目标入组 72 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Patients of either sex aged above 18 years.
•2.Patients who are able to understand written and/or verbal instructions and are ready to comply with all study requirements with a willingness to participate and give written informed consent voluntarily.
•3.Patients who had been diagnosed with body pain disorders like knee pain, low back pain and primary type of headache disorders like migraine, tension type headache and other primary head ache disorders.

•1.Women of child bearing potential who are either unwilling or unable to use an acceptable method of birth control [such as oral contraceptives, other hormonal contraceptives (implants or injectable products, vaginal products, skin patches), or IUDs, barrier methods] to avoid pregnancy during the study period.
•2.Secondary type of headache disorders, known spinal disc herniation and osteoporosis.
•3.Known allergy to compounds of investigational product.
•4.Subjects who had a diagnosis of basilar or hemiplegic migraine.
•5.Patients suffering from medical or psychiatric conditions that would increase the risk of adverse events or interfere with study assessments.
•6.Participation in an investigational drug trial in the 30 days prior to the screening visit.
•7.Immuno-compromised(history) individuals like known HIV positive patients or patients who are on treatment with steroids or immunomodulators.
•8.Patients of vulnerable group (children, lactating mother, elderly >80 years, handicapped, seriously ill, mentally challenged).
•9.History of drug or alcohol abuse during the last 6 months.

发起方